StockNews.com Begins Coverage on NeuroMetrix (NASDAQ:NURO)

Analysts at StockNews.com started coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the medical device company’s stock.

NeuroMetrix Price Performance

NASDAQ:NURO opened at $4.58 on Friday. The business has a 50 day moving average of $3.88 and a 200 day moving average of $3.86. The company has a market capitalization of $9.21 million, a price-to-earnings ratio of -0.73 and a beta of 2.29. NeuroMetrix has a 1-year low of $2.66 and a 1-year high of $5.56.

NeuroMetrix (NASDAQ:NURO) last released its earnings results on Tuesday, August 6th. The medical device company reported ($0.74) earnings per share for the quarter. The firm had revenue of $0.77 million during the quarter. NeuroMetrix had a negative return on equity of 41.74% and a negative net margin of 181.04%.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.